Gemcitabine And Cisplatin (Gp) Induction Chemotherapy (Ic) Plus Concurrent Chemoradiotherapy (Ccrt) Versus Ccrt Alone In Locoregionally Advanced Nasopharyngeal Carcinoma (Npc): A Phase 3, Multicenter, Randomized Controlled Trial.
Jun Ma,Yuan Zhang,Ying Sun,Fangyun Xie,Weihan Hu,Guoqing Hu,Ning Zhang,Kun-Yu Yang,Xiaodong Zhu,Feng Jin,Zhi-Bin Cheng,Mei Shi,Fei Han,Ye Tian,Yan Sun,Hao-Yuan Mo,Jin-Gao Li
DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.6003
IF: 45.3
2019-01-01
Journal of Clinical Oncology
Abstract:6003 Background: GP regimen has been established as the standard first-line treatment option for patients with recurrent/metastatic NPC. However, its efficacy in locoregionally advanced disease remains unclear. Methods: Patients with previously untreated, non-metastatic stage III-IVB (except T3-4N0M0, AJCC 7 th ) NPC, aged 18–64 years without severe comorbidities were eligible. They were randomly assigned (1:1) to receive GP IC (gemcitabine 1 g/m 2 on days 1 & 8, cisplatin 80 mg/m 2 on day 1, q3w for 3 cycles) plus CCRT (cisplatin 100 mg/m 2 , q3w for 3 cycles, concurrently with intensity-modulated radiotherapy) or CCRT alone. The primary endpoint was failure-free survival (FFS). The calculated sample size was 238 per group, with an 80% power (two-sided α 0.05) to detect a treatment failure hazard ratio (HR) of 0.52. Results: From Dec 2013 to Sep 2016, 480 patients from 12 centers were randomly assigned to IC+CCRT (n = 242) or CCRT alone (n = 238) group. Baseline characteristics were well balanced. After a median follow-up of 39 months, 3-year FFS was 85.8% in the IC+CCRT group and 77.2% in the CCRT alone group (intention-to-treat population; HR 0.53, 95% confidence interval 0.34–0.81; P = 0.003). In GP+CCRT group, 239 patients started GP IC and 231 (96.7%) completed all three cycles. The most common ≥grade 3 adverse events (AE) in IC+CCRT and CCRT group were mucositis (28.9% vs. 32.1%), neutropenia (28.0% vs. 10.5%) and leukopenia (26.4% vs. 20.3%). Conclusions: Adding GP IC to CCRT significantly improved FFS in locoregionally advanced NPC and is well tolerated with favorable toxicity profile. Clinical trial information: NCT01872962. [Table: see text]